BR112012018256A8 - método de tratamento de doença de parkinson - Google Patents
método de tratamento de doença de parkinsonInfo
- Publication number
- BR112012018256A8 BR112012018256A8 BR112012018256A BR112012018256A BR112012018256A8 BR 112012018256 A8 BR112012018256 A8 BR 112012018256A8 BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A8 BR112012018256 A8 BR 112012018256A8
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- amount ranging
- parkinson
- carbidopa
- disease
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 abstract 5
- 229960004205 carbidopa Drugs 0.000 abstract 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 4
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 2
- 229960003337 entacapone Drugs 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 abstract 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 abstract 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31039810P | 2010-03-04 | 2010-03-04 | |
| US41282110P | 2010-11-12 | 2010-11-12 | |
| US201161438416P | 2011-02-01 | 2011-02-01 | |
| PCT/FI2011/000013 WO2011107653A2 (en) | 2010-03-04 | 2011-03-03 | Method for treating parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012018256A2 BR112012018256A2 (OSRAM) | 2011-09-09 |
| BR112012018256A8 true BR112012018256A8 (pt) | 2017-12-19 |
Family
ID=44065577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018256A BR112012018256A8 (pt) | 2010-03-04 | 2011-03-03 | método de tratamento de doença de parkinson |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20130137729A1 (OSRAM) |
| EP (1) | EP2542220B1 (OSRAM) |
| JP (2) | JP5774610B2 (OSRAM) |
| KR (1) | KR101868326B1 (OSRAM) |
| CN (1) | CN102781424B (OSRAM) |
| AU (1) | AU2011222856B2 (OSRAM) |
| BR (1) | BR112012018256A8 (OSRAM) |
| CA (1) | CA2784819C (OSRAM) |
| EA (1) | EA026419B1 (OSRAM) |
| ES (1) | ES2614179T3 (OSRAM) |
| IL (1) | IL221744A (OSRAM) |
| MX (1) | MX336187B (OSRAM) |
| WO (1) | WO2011107653A2 (OSRAM) |
| ZA (1) | ZA201205836B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102816157B (zh) | 2005-07-26 | 2016-05-18 | 比艾尔-坡特拉有限公司 | 作为comt抑制剂的硝基儿茶酚衍生物 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| LT2481410T (lt) | 2007-01-31 | 2016-11-10 | Bial - Portela & Ca., S.A. | Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu |
| BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| US9132094B2 (en) | 2009-04-01 | 2015-09-15 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| EP2542220B1 (en) * | 2010-03-04 | 2016-11-02 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2012147099A1 (en) * | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| CA2858025C (en) | 2011-12-13 | 2020-09-22 | Bial-Portela & Ca., S.A. | 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-2-hydroxy-3-methoxy-1-nitrobenzene as an intermediate to prepare a catechol-o-methyltransferase inhibitor |
| CA3178035A1 (en) * | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
| WO2014151742A1 (en) * | 2013-03-15 | 2014-09-25 | Mylan, Inc. | Formulation containing carbidopa, levodopa, and entacapone |
| EP2799065A1 (en) * | 2013-04-30 | 2014-11-05 | Deva Holding Anonim Sirketi | Levodopa carbidopa entacapone pharmaceutical formulations |
| US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| HRP20192250T1 (hr) * | 2015-08-27 | 2020-05-15 | Prexton Therapeutics Sa | Derivat kromon oksima koji prodire u mozak za liječenje diskinezije uzrokovane levodopom |
| EP3768263B1 (en) * | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| EP3880210A1 (en) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN112741808B (zh) * | 2019-10-29 | 2024-02-06 | 南京济群医药科技股份有限公司 | 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法 |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| WO2021207634A1 (en) * | 2020-04-10 | 2021-10-14 | Senda Biosciences, Inc. | Biomarkers related to parkinson's disease and methods of using the same |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| GB202212082D0 (en) * | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| WO2024117683A1 (ko) * | 2022-11-30 | 2024-06-06 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462536A (en) | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| GB2238047B (en) | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
| US5607969A (en) | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| EP1713768A2 (de) | 2003-12-31 | 2006-10-25 | Cilag AG | Neue kristalline formen von entacapone und deren herstellung |
| MX339690B (es) | 2004-06-04 | 2016-06-06 | Xenoport Inc | Profarmacos de levodopa y sus composiciones y usos. |
| WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| CA2611114C (en) * | 2005-06-08 | 2014-09-23 | Orion Corporation | An entacapone-containing oral dosage form |
| MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| CN102816157B (zh) | 2005-07-26 | 2016-05-18 | 比艾尔-坡特拉有限公司 | 作为comt抑制剂的硝基儿茶酚衍生物 |
| ES2391575T3 (es) | 2005-12-05 | 2012-11-27 | Xenoport, Inc. | Mesilato de profármaco de Levodopa, sus composiciones y sus usos |
| EP2104424A4 (en) | 2006-10-30 | 2011-06-15 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA |
| BRPI0908340A2 (pt) | 2008-02-28 | 2018-12-26 | Bial Portela & Ca Sa | composição farmacêutica para fármacos pouco solúveis |
| AU2009283814B2 (en) * | 2008-08-22 | 2014-05-01 | Wockhardt Research Centre | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| UA106877C2 (uk) * | 2008-08-22 | 2014-10-27 | Вокхардт Рісерч Сентер | Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| EP2233131A1 (en) | 2009-03-23 | 2010-09-29 | Laboratorios Lesvi, S.L. | Pharmaceutical composition containing levodopa, entacapone and carbidopa |
| EP2542220B1 (en) * | 2010-03-04 | 2016-11-02 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| JP5551001B2 (ja) | 2010-06-22 | 2014-07-16 | 株式会社Ｐｆｕ | 摩擦係数推定装置および摩擦係数推定方法 |
| JP2015006373A (ja) * | 2014-07-14 | 2015-01-15 | 株式会社大都技研 | 遊技台 |
-
2011
- 2011-03-03 EP EP11709446.6A patent/EP2542220B1/en active Active
- 2011-03-03 US US13/582,427 patent/US20130137729A1/en not_active Abandoned
- 2011-03-03 JP JP2012555453A patent/JP5774610B2/ja active Active
- 2011-03-03 CN CN201180012312.9A patent/CN102781424B/zh active Active
- 2011-03-03 AU AU2011222856A patent/AU2011222856B2/en active Active
- 2011-03-03 BR BR112012018256A patent/BR112012018256A8/pt not_active IP Right Cessation
- 2011-03-03 CA CA2784819A patent/CA2784819C/en active Active
- 2011-03-03 EA EA201290865A patent/EA026419B1/ru not_active IP Right Cessation
- 2011-03-03 WO PCT/FI2011/000013 patent/WO2011107653A2/en not_active Ceased
- 2011-03-03 KR KR1020127025501A patent/KR101868326B1/ko active Active
- 2011-03-03 MX MX2012010161A patent/MX336187B/es unknown
- 2011-03-03 ES ES11709446.6T patent/ES2614179T3/es active Active
-
2012
- 2012-08-02 ZA ZA2012/05836A patent/ZA201205836B/en unknown
- 2012-09-02 IL IL221744A patent/IL221744A/en active IP Right Grant
-
2014
- 2014-10-02 US US14/504,925 patent/US10857120B2/en active Active
-
2015
- 2015-05-01 JP JP2015094429A patent/JP2015180644A/ja active Pending
-
2020
- 2020-10-07 US US17/064,759 patent/US11771675B2/en active Active
-
2023
- 2023-08-25 US US18/455,759 patent/US20240050394A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102781424A (zh) | 2012-11-14 |
| CN102781424B (zh) | 2016-03-30 |
| AU2011222856A1 (en) | 2012-07-26 |
| WO2011107653A2 (en) | 2011-09-09 |
| JP5774610B2 (ja) | 2015-09-09 |
| MX336187B (es) | 2016-01-07 |
| IL221744A (en) | 2016-11-30 |
| WO2011107653A8 (en) | 2012-08-02 |
| US20210085635A1 (en) | 2021-03-25 |
| AU2011222856B2 (en) | 2015-10-15 |
| ES2614179T3 (es) | 2017-05-30 |
| CA2784819C (en) | 2018-02-13 |
| EA201290865A1 (ru) | 2013-02-28 |
| WO2011107653A3 (en) | 2011-11-03 |
| BR112012018256A2 (OSRAM) | 2011-09-09 |
| EP2542220B1 (en) | 2016-11-02 |
| EP2542220A2 (en) | 2013-01-09 |
| US20150150839A1 (en) | 2015-06-04 |
| EA026419B1 (ru) | 2017-04-28 |
| US11771675B2 (en) | 2023-10-03 |
| US20240050394A1 (en) | 2024-02-15 |
| JP2015180644A (ja) | 2015-10-15 |
| ZA201205836B (en) | 2014-01-29 |
| US20130137729A1 (en) | 2013-05-30 |
| CA2784819A1 (en) | 2011-09-09 |
| KR20130006638A (ko) | 2013-01-17 |
| MX2012010161A (es) | 2012-10-03 |
| JP2013521263A (ja) | 2013-06-10 |
| HK1177896A1 (zh) | 2013-08-30 |
| KR101868326B1 (ko) | 2018-06-19 |
| US10857120B2 (en) | 2020-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018256A8 (pt) | método de tratamento de doença de parkinson | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| CU20110153A7 (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
| BR112013000190A2 (pt) | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide | |
| NZ713202A (en) | Diagnosis and treatments relating to th2 inhibition | |
| NZ610911A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| NZ595189A (en) | Combination therapy with thiocolchicine derivatives | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| CR20130259A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| BR112014009265A2 (pt) | micelas de proteína de soro do leite contra atrofia muscular e sarcopenia | |
| BR112014030813A2 (pt) | tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson | |
| ECSP11011082A (es) | Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| UA105644C2 (uk) | Способи лікування легеневих порушень складами ліпосомального амікацину | |
| CO6592101A2 (es) | Metodos para tratar ulceras de pie de diabetico | |
| BR112014002885A2 (pt) | uso de composto orgânico para o tratamento da síndrome de noonan | |
| JP2019529569A5 (OSRAM) | ||
| UY31826A (es) | Compuesto peptídico y su uso | |
| WO2011121607A3 (en) | Rasagiline and its pharmaceutically acceptable salts | |
| NZ602032A (en) | Oral b12 therapy | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |